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Abstract: The transcription factor Ets-1 (ETS proto-oncogene 1) shows low expression levels except
in specific biological processes like haematopoiesis or angiogenesis. Elevated levels of expression are
observed in tumor progression, resulting in Ets-1 being named an oncoprotein. It has recently been
shown that Ets-1 interacts with two DNA repair enzymes, PARP-1 (poly(ADP-ribose) polymerase 1)
and DNA-PK (DNA-dependent protein kinase), through two different domains and that these
interactions play a role in cancer. Considering that Ets-1 can bind to distinctly different domains of
two DNA repair enzymes, we hypothesized that the interaction can be transposed onto homologs of
the respective domains. We have searched for sequence and structure homologs of the interacting
ETS(Ets-1), BRCT(PARP-1) and SAP(DNA-PK) domains, and have identified several candidate
binding pairs that are currently not annotated as such. Many of the Ets-1 partners are associated to
DNA repair mechanisms. We have applied protein-protein docking to establish putative interaction
poses and investigated these using centrality analyses at the protein residue level. Most of the
identified poses are virtually similar to our recently established interaction model for Ets-1/PARP-1
and Ets-1/DNA-PK. Our work illustrates the potentially high number of interactors of Ets-1, in
particular involved in DNA repair mechanisms, which shows the oncoprotein as a potential important
regulator of the mechanism.
Keywords: Ets-1; oncoprotein; DNA repair; biological networks; protein-protein interaction; Residue
Interaction Networks
1. Introduction
Ets-1 (ETS proto-oncogene 1) is a transcription factor involved in specific biological processes
related to development, hematopoiesis, angiogenesis or osteogenesis. The gene is usually expressed in
delimited time frames associated to these physiological processes but was also found as overexpressed
in diseases like rheumatoid arthritis, atherosclerosis and cancers. This association to cancers makes
Ets-1 an oncogene. It is involved more precisely in cancer progression and shows abnormally high
levels of expression in invasive cells. Recently, we showed experimentally that Ets-1 interacts
with two DNA repair enzymes, namely PARP-1 (poly(ADP-ribose) polymerase 1) and DNA-PK
(DNA-dependent protein kinase) and characterized their domains of interaction [1,2]. The ETS
(Erythroblast Transformation Specific) domain of Ets-1 can interact with the BRCT (BRCA1 C-terminal)
domain of PARP-1 or the SAP (SAF-A/B, Acinus and PIAS) domain of Ku70 (70 kDa unit), a subunit of
the DNA-PK DNA repair complex. Moreover, we characterized the binding modes of these interactions
considering the domains of the Homo sapiens Ets-1, PARP-1 and Ku70 proteins [3]. We found that the
binding should occur on the α-helix H1 of the ETS domain, leaving helix H3 available for DNA-binding,
and identified a hydrophobic patch in H1 as a central patch of the interaction, which includes three
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tryptophans (Trp338, Trp356 and Trp361) of Ets-1. Additional residues, Leu342 and Gln339, were also
identified in the core of the interface.
DNA repair enzymes act as guardians of the integrity of the genome. Disruption in their pathways
have often been associated to disease-related phenotypes, in particular cancers [4,5]. They also play
a crucial role in treatments of cancerous cells based on DNA breaks generation like radiotherapy or
chemotherapy. Different mechanisms permit to fix damaged DNA depending on the type of lesion.
These are divided into two categories, namely single-strand DNA (ssDNA) and double-strand DNA
(dsDNA) repair mechanisms. ssDNA itself gathers three types of mechanisms that are base excision
repair, nucleotide excision repair and mismatch repair pathways [6]. For dsDNA repair, two general
mechanisms, called non-homologous end joining pathways (classical-NHEJ and alternative-NHEJ) and
homologous recombination pathways (HR and Single Strand Annealing), are involved, of which the
activation depends on the amount of 5′ end resection at the double-strand break [6]. These pathways
require many enzymes to work together or sequentially. PARP-1 DNA repair focuses mainly on ssDNA
but also promotes the HR pathway and limited end resection for the alternative NHEJ pathway while
DNA-PK is known to be involved in dsDNA repair through the classical NHEJ pathway. The catalytic
inhibition of PARP-1 in invasive cancerous cells was shown to enhance the accumulation of Ets-1 in
the cell and lead to partial cell death [1]. This effect shows an essential role of the partnership between
PARP-1 and Ets-1 in invasive cancerous cells. It also raises the question if other DNA repair enzymes
could act with Ets-1 in Ets-1 related cancers, which would show this protein as a general perturbator
of DNA repair mechanisms.
Considering that Ets-1 is able to bind two different DNA repair enzymes through its ETS domain,
we hypothesized that the oncoprotein is able to bind other proteins, potentially involved in DNA
repair, as well. We searched for homologs of the ETS, BRCT and SAP domains and identified several
candidate binding pairs, of which we then focused on proteins annotated as being associated to DNA
repair. We present the method we used based on both sequence and structure information to identify
homologs and the different network approaches to identify these new potential partners that are not
present in the ego protein-protein network of Ets-1. We discovered new potential interactors of Ets-1
and discussed those associated to DNA repair mechanisms.
2. Materials and Methods
The workflow of the work described in this article is depicted as a diagram in Figure 1. It is
divided into several parts: the research of homologs, the construction of the protein-protein interaction
networks (PPIN) and regulatory network (RN), the docking of the domains and the generation of the
corresponding Residue Interaction Networks (RIN). Each step is described below.
The list of the potential partners identified with their eventual annotation as belonging to DNA
repair pathways is given in supplementary data (Supplementary Table S1).
2.1. Homologs
The sequences of the ETS, BRCT and SAP domains of the Homo sapiens Ets-1, PARP-1 and Ku70
(also called XRCC6: X-ray repair cross complementing 6) proteins were retrieved from Uniprot:
- ETS: P14921, residues 331 to 415
- BRCT: P09874, residues 388 to 486
- SAP: P12956, residues 536 to 609
The structures of these domains were retrieved from PDB (Protein Data Bank) or modeled and
cut with respect to these positions:
- ETS: 1GVJ (331–415)
- BRCT: I-Tasser [7] model (388–486) based on the 2COK structure (BRCT domain which bears a
mutation P480S)
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- SAP: I-Tasser model (536–609) based on the 1JEQ structure (limited SAP domain)
Sequence homologs were retrieved with BLASTP [8,9] queried with the sequences of the domains
on the RefSeq [10] databanks. Only identifiers starting with “NP_” and results with an e-value ≤
1×10−4 were retained.
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Figure 1. Workflow diagram of the identification of potential partners of Ets-1 involved in DNA repair
mechanisms. Homologs are d picted in dark blue, networks in light blue, docking in orange and
results in green. Ets-1: ETS proto-oncogene 1; PARP-1: poly (ADP-ribose) polymerase 1; Ku70: 70 kDa
unit (or XRCC6: X-ray re air cross c mplementing 6); ETS: Erythroblast Transfor ation Specific; BRCT:
BRCA1 C-terminal; SAP: SAF-A/B, Acinus and PIAS; PPI: Protein-Protein Interaction.
Structural homologs were retrieved with BLASTP queried on the PDB databank (e-value ≤
1×10−4), with Dali [11] and with Kpax 3.1.0 [12] performed on CATH 4.0 [13], SCOP 2.04 [14] and on
Dali results (for a filtering of these results). For Dali, only structures with a Z-score ≥ 2 were kept.
For Kpax, the 200 best structures were conserved and only t ose with H-score > 0.4. A second order
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polynomial regression performed on CATH 4.0 and SCOP 2.04 structures shows that such a H-score
corresponds roughly to a TM-score > 0.5, which is indicative for fold conservation between output
and input [15]. Using the Kpax results, the sequences of the identified homologous structures were
submitted to BLASTP to identify sequence homologs of these structures. Only results with an e-value
≤ 1×10−4 and a percentage of identity ≥ 95% were conserved.
Interpro predictions were also retrieved for the respective domains [16] considering the identifiers
IPR000418 (ETS), IPR001357 (BRCT) and IPR003034 (SAP). Results were integrated in a common table
file per domain and are provided in Supplementary data (Supplementary Tables S2–S4).
For each domain, the sequences of all the homologs were clustered with USEARCH
8/UCLUST [17] with a percentage of identity≥ 95%. Then, if available in the Protein Data Bank, a Homo
sapiens structure was retrieved for each cluster. If several were available, the one that covered the entire
sequence of the domain, then the one with the best validation criteria was selected as representative
crystallographic structure. NMR (Nuclear Magnetic Resonance) structures were considered when no
crystallographic ones were available.
2.2. Domain-Domain Docking
The protein-protein docking runs between all the BRCT homologs and the ETS domain of Ets-1
on the one side, and between all the SAP homologs and the ETS domain of Ets-1 on the other side
were performed with ClusPro with default parameters [18]. Only domains for which the structures
were available in the PDB were used in the docking runs. The first model of the first cluster of the
resulting binding modes in balanced mode was used for the generation of the Residue Interaction
Networks (RIN).
2.3. Biological Networks
The Protein-Protein Interactions (PPI) network of Ets-1, PARP-1, Ku70 and the Homo sapiens
proteins, which bear at least one homologous domain to ETS, BRCT or SAP, was created from the
Intact database of curated interactions [19] in the Cytoscape network visualization and analysis
software [20,21] using their Uniprot ID. The list of fetched interactions was not filtered. Only the
proteins for which interactions were found in Intact appear in the network. Predicted interactions
of Ets-1, PARP-1 and Ku70 were retrieved from the FpClass database [22] through the web interface
(http://dcv.uhnres.utoronto.ca/FPCLASS/). The metatargetomes of Ets-1, PARP-1, BRCA1, PAXIP1,
XRCC1 and MAFG were obtained with the iRegulon app [23] for Cytoscape considering all the
predicted regulations (threshold of occurrence count in databases to 1), merged and filtered with
Cytoscape core tools. The predicted regulations were assigned based on the gene signatures of
GeneSigDB and MSigDB, and on gene sets built with the Ganesh clustering algorithm using default
settings to 91 microarray datasets [23]. Gene Ontology Enrichment was performed with the ClueGO
app [24] for Cytoscape with default settings, considering biological processes to identify genes/proteins
associated to DNA repair (GO:0006281).
Residue Interaction Networks (RINs) were generated for every best model of all the docking
runs performed between the ETS domain of Ets-1 and each homologous BRCT or SAP structure (one
representative structure of each group). They were created with an in-house C program considering
a residue-residue contact when the distance between any atom pair of both residues was found
between 2.5 Å and 5 Å. Residue Centrality Analyses (RCA) were performed with the RINspector
app [25,26] for Cytoscape. We considered as central a residue with a Z-score ≥ 2. More details are
given in Appendix A.
2.4. Expression Data
Expression data of the MDA-MB-231 cells and the MCF-7 were retrieved from the NCBI (National
Center for Biotechnology Information) Gene Expression Omnibus repository [27], from GSE32474
(NCI-60 dataset). They were compared in a differential analysis that was performed between the three
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replicates of each condition with R/Bioconductor using the affy [28] and limma packages [29]. Data
were normalized with RMA (Robust Multi-array Average) and a t-test was performed. p-values were
FDR (False Discovery Rate) corrected for multiple testing. Probes were filtered considering only those
with an adjusted p-value ≤ 0.01. These data were mapped onto the regulatory network.
3. Results
Because Ets-1 can interact with two different domains of two different DNA repair proteins,
namely the BRCT domain of PARP-1 and the SAP domain of Ku70 (also called XRCC6), through its
ETS domain, we hypothesized that ETS(Ets-1) could also interact with homologous BRCT or SAP
domains. Following the workflow depicted in Figure 1, we first identified proteins that contain at least
one domain homologous to ETS(Ets-1), BRCT(PARP-1) or SAP(Ku70). In order to then identify which
of these are good candidates, we first retrieved experimentally verified interactions between them
and then extended the set to predicted interactions of Ets-1, PARP-1 or Ku70. We focused on proteins
involved in DNA repair and also considered predicted regulations in order to evaluate a potential
interoperability between Ets-1 and a partner. In this regulatory network, we integrated expression
data, comparing cancerous cells with high Ets-1 expression levels to cancerous cells with low Ets-1
expression levels, and thus, evaluate the effect of Ets-1 on the expression of potential partners. Finally,
we performed protein-protein docking between ETS(Ets-1) and identified BRCT and SAP homologs.
These were followed by Residue Interaction Networks analyses to compare the predicted binding
modes to the established ones for ETS(Ets-1)/BRCT(PARP-1) and ETS(Ets-1)/SAP(Ku70) [3].
3.1. Homologs
Knowing that the ETS domain of Ets-1 can bind the BRCT domain of PARP-1 or the SAP domain
of Ku70, we searched for sequence and structure homologs of the individual domains of BRCT(PARP-1)
and SAP(Ku70), in order to identify new additional binding partners of ETS(Ets-1). ETS(Ets-1)
homologs were also searched to identify some of them that are known to bind to BRCT and/or
SAP homologs in the following protein-protein interaction network, which would allow to infer a
potential binding by ETS(Ets-1) as well. The homologs found are gathered in three different tables
in Supplementary data, one for each domain, and clustered in function of their similarity of protein
sequences (see Materials and Methods section for details). We assigned a structure to each cluster if
one was available in the Protein Data Bank. The number of homologous genes, PDB structures found
and clusters of sequences are listed in Table 1. The differences in numbers between genes and clusters
can be explained by the fact that one gene can bear several BRCT domains, with amino acid sequences
that are more or less similar.
Table 1. Number of homologous genes, PDB structures and clusters of sequences found for the ETS,
BRCT and SAP domains. Each cluster gathers sequences which share at least 95% identity
Homologs
Domain Number of Genes Number of PDB Structures Number of Sequence Clusters
ETS 42 23 38
BRCT 19 24 30
SAP 19 10 19
PDB: Protein Data Bank; ETS: Erythroblast Transformation Specific; BRCT: BRCA1 C-terminal; SAP: SAF-A/B,
Acinus and PIAS.
24 BRCT and 10 SAP clusters have a representative PDB structure that was then used in
protein-protein docking essays against the ETS domain of Ets-1 (see below).
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3.2. Protein-Protein Interaction Network
3.2.1. Experimentally Characterized Interactions
We used the Uniprot identifiers of the Ets-1, PARP-1 and Ku70 (or XRCC6) proteins and of the
found homologs to query the Intact database and retrieve the curated interactions between them.
Figure 2a shows the resulting network, it presents direct edges between the proteins and their first
neighbors. The homologs were gathered in a grid layout, each group being split into two subgroups:
those that were known to bear an ETS, BRCT or SAP domain following the Interpro annotation (in
diamonds) and the other homologs that we have found with our method. Only the BRCT group
did not show any such homologs. Given the complexity of the graph, we decided to focus on the
interactors shared by at least two groups of homologs (Figure 2b). Although we did not filter any edges
in the graph on the type of interaction, in order to conserve the maximum amount of information on
interactors between the different groups, the graph shows very few of them between the individual
groups. The majority of interactions retrieved from Intact between the ETS group and the two others
were focused on PARP-1 and Ku70 (XRCC6) (highlighted in orange for Ets-1 interactions). Nevertheless,
we identified an interaction between the ERG protein of the ETS group and HNRNPU of the SAP
group. The other ones were indirect through other proteins.
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Ku70. (a) Global first neighbor PPI network; ETS homologs are colored blue, BRCT homologs are 
colored yellow and SAP homologs are red; first neighbors of ETS, BRCT and SAP homologs are shown 
at the extremities of the graph and plotted in another shade of blue, yellow and red, respectively; 
common interactors between different types of homologs are colored in a mix of colors of the 
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Figure 2. Hu t in-protein interaction (PPI) netw rk of Ets-1, ARP-1, Ku70, and proteins that
bear a domain l g to the ETS domain of Ets-1, BRCT domain of PARP-1 and SAP d main of
Ku70. (a) Global first neighbor PPI network; ETS homologs are colored blue, BRCT homologs are
colored yellow and SAP homologs are red; first neighbors of ETS, BRCT and SAP homologs are shown
at the extremities of the graph and plotted in another shade of blue, yellow and red, respectively;
common interactors between different types of homologs are colored in a mix of colors of the homologs,
resulting in green for ETS and BRCT, purple for ETS and SAP, and orange for SAP and BRCT; proteins
that interact with at least one protein of each group of homologs are colored grey. (b) Central network
delimited by the dashed square in (a), only interactors that are shared between at least two groups
are conserved; diamond forms are the proteins that were annotated by Interpro as containing a ETS,
BRCT or SAP domain, ellipses are the additional homologs we have found, using our method; rounded
rectangles are identified interactors; orange edges indicate known interactions with Ets-1.
3.2.2. Predicted Interactions
To increase the number of edges between the ETS group and the BRCT and SAP groups, we added
predicted interactions from the FpClass database for Ets-1, PARP-1 and Ku70 (XRCC6) (Figure 3a).
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We conserved only the shared interactors between the three proteins like we did for the three groups
of homologs for the Intact PPI network and merged the FpClass and Intact networks (Figure 3c).
The final network (Figure 3d) shows only the proteins of the three groups of homologs and depicts
additional links between the three groups, in particular between (i) Ets-1 and BARD1, BRCA1, NBN,
TP53BP1, XRCC1 of the BRCT homologs, (ii) between RPA2, TERF2, H1FX, E2F5, ELF1, ADAR of the
ETS homologs and PARP-1, (iii) between Ets-1 and HNRNPUL1, PIAS4, PIAS2, HNRNPU, MAFG,
PIAS1, DEK, PIAS3 of the SAP homologs and (iv) between H1FX, ETS2, TERF2, HSF1, CUL1, IRF3,
RPA2 of the ETS homologs and Ku70.
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Figure 3. Predicted and experimentally identified protein-protein interaction (PPI) network of
Ets-1, PARP-1, Ku70 and proteins that contain one of the ETS, BRCT or SAP homologous domains:
(a) first-neighbour predicted network of Ets-1, PARP-1 and Ku70 (XRCC6); predictions were retrieved
from FpClass; the group of ETS homologs is colored blue, the one of BRCT homologs is colored yellow
and the one of SAP homologs is colored red; (b) global first neighbor PPI network; this is the same
network as in Figure 2a; (c) union of the center part of the networks (a,b), the color code of the nodes
is the same as in Figure 2; edges are colored green for experimentally established interactions and
dashed/grey for predicted ones; (d) the same network as (c), keeping only the proteins of the three
groups of homologs.
3.3. DNA Repair
Considering the predicted and experimentally determined interactions between the homologs of
ETS and those of BRCT or SAP, we hypothesized that some of the last two groups could constitute
potential partners of the Ets-1 protein, especially those involved in DNA repair mechanisms, seeing
that Ets-1 also interacts with PARP-1 and DNA-PK. Focusing on the merged PPI network of the
homologs and common partners (Figure 3c), we annotated and filtered the network according to their
association to DNA repair activities with the ClueGO app for Cytoscape. We obtained the PPI network
depicted in Figure 4a, where we kept all the proteins of the three homologs groups. We filtered the
Genes 2019, 10, 206 8 of 17
network to conserve (i) the proteins of the three groups of homologs, (ii) the proteins that are not
involved in DNA repair but that make bridges between the proteins of the group of the ETS homologs
and the proteins of the group of the SAP or BRCT homologs involved in DNA repair and (iii) the
proteins of the SAP or BRCT group that are not annotated as belonging to DNA repair mechanisms
but that are connected to a protein that is involved in DNA repair and makes a bridge with the ETS
group. Because the interactions Ets-1/PARP-1 and Ets-1/Ku70 are already known, we removed them
from the network (Figure 4b).
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experimentally verified interactions and dashed/grey for predicted ones. (b) The same network as in
(a) but PARP-1 and Ku70(XRCC6) were removed; subsequently, only the proteins that connect a ETS
homolog to a BRCT or SAP homolog were conserved, one of the ETS homolog partners being involved
in DNA repair.
This last network shows 14 candidates for binding to Ets-1 relating t DNA repair mechanism.
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FpClass and involved in DNA repair mechanisms), (ii) DEK and PIAS4 for SAP homologs (same
reason), (iii) LIG3, MDC1, EMD, PIAS1, PIAS2, HNRNPUL1 and TMPO (interact with a protein
involved in DNA repair that is predicted to interact with Ets-1 or interacts with an ETS homolog).
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cells in which high levels of expression of Ets-1 are measured, while MCF-7 cells are non-invasive cells
that show low levels of expression of Ets-1. With iRegulon, we found the metatargetomes of Ets-1
(9904 predicted regulations by Ets-1), BRCA1 (855 predicted regulations), PARP-1 (1529 predicted
regulations), PAXIP1 (336 predicted regulations), XRCC1 (302 predicted regulations) and MAFG
(4206 predicted regulations). We merged and filtered them conserving only the subset of proteins of
Figure 4b and mapped expression data onto the resulting network (Figure 5).
In this regulatory network, only PARP-1, XRCC1, NBN and PAXIP1 appear to show a significant
log2(Fold Change) signal and are involved in DNA repair mechanisms. Their differential signal
is negative except for PARP-1. Therefore, while PARP-1 was overexpressed, XRCC1, NBN and
PAXIP1 were repressed in MDA-MB-231 compared to MCF-7 which indicates that the amount of
the corresponding proteins should be lowered as well, thus resulting in a limited repair activity, while
Ets-1 gene expression is higher. Nevertheless, the three DNA repair genes still showed a relatively
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high signal of expression compared to the other genes of the samples (percentile rank > 50% within
the samples) and the amount of Ets-1 proteins is elevated in MDA-MB-231. The other homologs
do not show differential expression (depicted in grey in Figure 5); however, they all show relatively
good levels of expression in MDA-MB-231 (percentile rank > 50% within the samples). Thus, we did
not see a strong signal of regulation by Ets-1 of the new potential partners involved in DNA repair.
Consequently, any correlated activity between Ets-1 and the identified DNA repair proteins is likely to
result from an interaction at the protein level, which cannot be identified with the gene signatures used
by iRegulon for the construction of the regulatory network. These interactions were made possible
because Ets-1 and these DNA repair genes showed good levels of expression. Furthermore, two
DNA repair proteins appear as exceptions in this regulatory network, namely PARP-1 and XRCC1.
These proteins, amenable to regulation by Ets-1, could also in turn regulate Ets-1, highlighting a tight
connection between them. MAFG also shows such a reciprocal regulation with Ets-1.
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3.4. Protein-Protein Docking and Residue Interaction Networks
To confirm the relevance of these potential candidates, we performed docking runs between
the ETS domain of Ets-1 and the BRCT or SAP homologous domains of each cluster identified. The
representative structures of the BRCT or SAP clusters were used and docking only performed for
those clusters for which a structure was available (24 for BRCT homologs, 10 for SAP homologs).
Subsequently, we ran Residue Centrality Analyses on the best model of each run to identify central
residues at the interface and to compare them to the residues identified in [3] for the binding of
ETS(Ets-1)/BRCT(PARP-1) and ETS(Ets-1)/SAP(Ku70) (see Appendix A). We calculated these for four
sets of structures: all the structures available for the BRCT homologs and the SAP homologs, and the
two subsets of those that are associated to DNA repair mechanisms. Table 2 shows the residues of the
ETS(Ets-1) domain that were found as central in at least two structures and that belong to the interface.
Three residues are found in all the groups, namely Trp338, Trp356 and Trp361, with a systematic
presence of Trp361 at the interface and with a high Z-score in all the structures (except one Z-score ≥ 2
for one BRCT structure). Leu342 also appears in the ETS/SAP binding pairs, while Gln339 appears in
the ETS/BRCT pairs. With the exception of Thr346, these residues are part of a hydrophobic patch that
was identified previously [3]. All the first poses of the docked structures of the homologs show an
interaction with the α-helix H1 of ETS, involving the same ETS residues as for the interaction with
PARP-1 and Ku70. This is a strong argument that the identified homologs can be considered good
candidates for the binding to the ETS domain of Ets-1.
Table 2. Residues of the ETS domain of Ets-1 found at the interface that have a Residue Centrality
Analysis Z-score ≥ 2 at least twice in the set of structures. The table shows the number of times the
residue is found (written “Nb”) at the interface and the number of times it has a Z-score ≥ 2. It presents
the results for four sets of structures: all ETS/SAP homologs (10 structures), ETS/SAP homologs
involved in DNA repair (5 structures), all ETS/BRCT homologs (24 structures) and ETS/BRCT
homologs involved in DNA repair (18 structures).
ETS/SAP Homologs—All
Residue Nb Interface Nb Z-Score≥ 2
Trp361 10 10
Leu342 10 5
Trp338 10 5
Trp356 10 3
ETS/SAP homologs—DNA repair
Trp361 5 5
Leu342 5 2
Trp338 5 2
Trp356 5 2
ETS/BRCT homologs—All
Trp361 24 23
Trp338 24 9
Thr346 24 6
Gln339 24 5
Trp356 24 5
Phe414 24 3
Glu343 24 2
ETS/BRCT homologs—DNA repair
Trp361 18 17
Trp338 18 7
Thr346 18 6
Gln339 18 4
Trp356 18 3
Phe414 18 3
4. Discussion
We recently demonstrated that the ETS domain of Ets-1 can interact with the BRCT domain of
PARP-1 or with the SAP domain of Ku70, a subunit of the DNA-PK complex, both of them being
involved in DNA repair mechanisms [1,2]. Based on the similarity of binding modes [3], we searched
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for sequence and structure homologs of these ETS, BRCT and SAP domains, in order to identify new
potential partners of the Ets-1 oncoprotein, focusing on those potential partners that are involved in
DNA repair mechanisms. We identified 42 genes that express a protein domain homologous to the
ETS domain of Ets-1, 19 genes for the BRCT domain of PARP-1 and 19 genes for the SAP domain. We
assembled all the interactions known in the Intact database between these homologs and created a
protein-protein interaction network. The network was extended with predicted interactions from the
FpClass database. We then focused on proteins involved in DNA repair mechanisms. At this level, we
identified 14 relevant candidates for binding to the ETS domain of Ets-1, which are (i) BRCT homologs:
TP53BP1, XRCC1, BARD1, BRCA1, NBN, LIG3 and MDC1, and (ii) SAP homologs: DEK, PIAS4, EMD,
PIAS1, PIAS2, HNRNPUL1 and TMPO. We finally performed protein-protein docking simulations
with the representative PDB structures for each cluster of BRCT and SAP homologs versus the ETS
domain of Ets-1. We found the binding modes of the different homologs (to ETS) to be compatible
with the ones established in [3], involving the α-helix H1 of Ets-1 and a hydrophobic patch centered
around Trp361.
Among these, BRCA1 was not referenced in Intact at the time we performed this work, but found
as a predicted interactor by FpClass. However, this interaction has been identified experimentally
as a partner of Ets-1 [30]. It was shown that full-length Ets-1 interacts with BRCA1 and that the ETS
domain of Elk-1, a member of the ETS family, interacts with BRCA1, which stands as a validation
of our approach. BRCA1 has an activity in DNA repair but more specifically in double-stranded
DNA-breaks repair by the homologous recombination repair mechanism. Like PARP-1, it contains a
BRCT domain as potential binding partner for Ets-1. Legrand et al. [1] showed that when PARP-1 is
catalytically inhibited by PJ-34, MDA-MB-231 cells showed about half of the cells undergoing necrosis.
Under PARP-1 inhibition, unrepaired single-stranded DNA breaks lead to double-stranded breaks
during replication, which can be repaired, amongst others, by enzymes like BRCA1 and BRCA2.
Defects in these genes are commonly associated with an increased risk factor for breast cancer [31].
Therefore, BRCA1 interaction with Ets-1, which could happen through one of its BRCT domains, would
have an effect on double-stranded repair, thereby explaining the necrosis ratio of the MDA-MB-231
cells under PJ-34 treatment. This idea goes in the same direction as the model of synthetic lethality
mechanisms, which shows that PARP inhibitors kill tumors defective in BRCA1 or BRCA2 genes [6,31].
A known partner of BRCA1, namely BARD1 (BRCA1-associated RING domain protein 1), contains
two additional BRCT domains that could be targeted by Ets-1, offering multiple binding possibilities
of Ets-1 to the BRCA1/BARD1 complex. In BARD1, three point mutations have been found in breast
and/or ovarian cancer susceptible patients [32]. One of these, R658C, is located in the first BRCT
domain, close to the predicted interaction site with Ets-1.
Likewise, while not found in Intact, but predicted by FpClass, we identified TP53BP1 (TP53
Binding-protein 1). While TP53, a well-known tumor suppressor whose several mutations are
associated to various forms of cancer [4], is known to interact with Ets-1 [33,34], nothing is currently
known about a possible interaction between Ets-1 and TP53BP1. However, certain mutations in
TP53BP1 can also be associated to various cancers, more precisely to breast and skin cancers [4].
Obviously, TP53BP1 binds TP53, but more importantly, this protein is involved in the classical NHEJ
pathway, similar to DNA-PK. The binding of Ets-1 to TP53BP1 (through its BRCT domain) could have
an impact on the interplay between Ets-1 and TP53. Our data shows the possibility for these three
proteins to interact simultaneously: the superpositions of the five best representative docking poses
of one TP53BP1 BRCT domain versus the ETS domain of Ets-1 on the crystal structure of the BRCT
domains of TP53BP1 bound to TP53 (PDB ID: 1KZY [35]) shows that the ETS domain of Ets-1 could
bind the second BRCT domain of TP53BP1 without clashing with TP53 (Supplementary Figure S1).
Concerning NBN and XRCC1, gene expression levels measured in MDA-MB-231 (in which Ets-1
levels are high) are lower than in MCF-7 (in which Ets-1 levels are low) and Ets-1 is a potential regulator
of them. We see in our analysis that when Ets-1 is highly expressed in the invasive cells, these DNA
repair genes are repressed, which should have consequences on the ability of the cells to repair their
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DNA lesions. However, even if repressed, the two genes still show relatively good levels of expression
and probably still a reasonable amount of their proteins in the cells. Therefore, they could interact
with Ets-1 through its ETS domain and these interactions could play a role in DNA repair mechanisms.
Indeed, it was shown that mutations in the NBN gene are associated to an increase of a risk of breast
cancer through the double-stranded break repair mechanism [36]. XRCC1 mutants are also associated
with breast cancer [5,37]. For instance, mutation R399Q was found to be positively associated to breast
cancer, which is located at the end of the first BRCT domain of XRCC1 and at the interface of the
best binding mode predicted by Cluspro in the ETS(Ets-1)/BRCT(XRCC1) docking run (Figure 6).
The BRCT domain used for the docking (PDB ID: 2D8M) bears this Gln variant at position 399. With
an Arg at this position, the affinity between the two domains could be increased, with potential
stronger binding for the R399 variant through electrostatic interactions with both E343 and D347 of
the ETS(Ets-1) domain. In this model, the R399Q variant destabilizes the interaction between ETS and
XRCC1. Moreover, it is known that XRCC1 interacts with LIG3 for ligation to DNA through its second
BRCT domain [38,39], which is also involved in homodimeric formation, letting space for a potential
binding of Ets-1 to the first BRCT domain. Furthermore, it would be possible that ETS(Ets-1) binds
the second BRCT domain of XRCC1 potentially preventing the formation of functional oligomers.
In addition to this potential interaction between Ets-1 and XRCC1, Figure 5 presents a reciprocal
regulation between them, which shows a tight connection between the two proteins, as is the case for
Ets-1 and PARP-1. Ets-1 could even interact with LIG3 through its respective BRCT domain, enabling
the oncoprotein at several levels to disrupt the ligase activity of this complex in base excision repair or
alternative NHEJ pathways.
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repair pathways, especially in the base excision repair and classical non homologous end joining
pathways, for what is currently known [6,41]. No known or predicted interaction with Ets-1 can be
found in its PPI network; however, POLL is known to interact with the XRCC4-LIG4 complex through
its BRCT domain [42] and this interaction could potentially be disrupted by intervention of Ets-1
through its ETS domain.
Lastly, TOPBP1, involved in DNA repair and DNA replication, contains as many as eight BRCT
domains, making it a large target for Ets-1 to bind at least to one of them. Deregulated activity of
TOPBP1 has been associated to cancer, in particular breast cancer, and it is considered a potential target
for cancer therapy [43,44]. Similarly, PAXIP1 contains many BRCT domains (six domains) that might
be targeted by Ets-1.
Initially, we considered only known protein interaction pairs, including the interactions occurring
through homologous ETS and homologous BRCT or SAP. In our request to the Intact database, we only
found ERG of the ETS family interacting with the HNRNPU protein of the SAP homologs. However,
HNRNPU is not known to be involved in DNA repair. On the other hand, we already mentioned that
Elk-1, also of the ETS family, is known to interact with BRCA1. The interaction network shows that
several of the ETS homologs, including ERG, are known to interact with PARP-1 or DNA-PK [45].
Therefore, we cannot exclude a competitive binding between Ets-1 and members of the ETS family.
In cells overexpressing Ets-1, such as MDA-MB-231 cells, interactions with Ets-1 could be favored
because of the very high amount of the Ets-1 protein. The BRCT and SAP homologs that we found as
potential interactors with Ets-1 are more or less divergent in sequence composition, which inevitably
leads to various affinities in binding.
In Ets-1, the ETS domain contains two auto-inhibitory regions composed of four helices (HI-1,
HI-2, H4 and H5) that fold onto the ETS domain. Moreover, it possesses a Serine Rich Region (SRR)
upstream in the sequence (279-295) with some of them prone to phosphorylation, which may regulate
the auto-inhibition [46]. The binding between the H1 helix and the auto-inhibitory domains is weak
and can be easily destabilized [47]. Here, we limited our study to the ETS domain alone, without these
regulatory domains, corresponding to the situation where the auto-inhibition is already released. In our
context, this disruption would be provoked by the identified interaction partners prior to their binding
to H1. It has been shown that phosphorylation of the SRR domain enhances the auto-inhibition [46,48],
highlighting an important role of post-translational modifications in the binding to the ETS domain.
Therefore, taking into account the effect of potential post-translational modifications on binding would
be of high interest in a further extensive study.
Considering proteins that might bind to the ETS domain of Ets-1, that are involved in different
pathways of DNA repair, and this at different levels, it raises the question if Ets-1 could act as a general
regulator or perturbator of DNA repair, in particular in invasive cancerous cells where the gene is
overexpressed. Consequently, it could be of high interest to design inhibitors that alter the interaction
between the ETS domain of Ets-1 and its partners. This inhibition may have an impact on DNA repair
activity in invasive cancerous cells.
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Appendix A
Residue Interaction Networks (RINs) are networks generated from a PDB structure where nodes
are residues and any edge is a detected interaction between a pair of residues inside the structure. An
interaction was defined as any atom contact pair between 2.5 Å and 5 Å. The RINs were generated for
each best docking pose between the ETS domain of Ets-1 and a BRCT or SAP homolog. Consequently,
24 RINs were generated for ETS(Ets-1)/BRCT homologs and 10 RINs for ETS(Ets-1)/SAP homologs.
Once created, a Residue Centrality Analysis was performed, which is based on the change in average
shortest path length under removal of each node. The shortest path between two nodes in a network is
defined as the path with the least amount of edges connecting the first node to the second one, the
shortest path length then being the number of edges. The average shortest path length (ASPL) is the
average of shortest path lengths of all possible pairs of nodes in a network. In the residue centrality
analysis, a per-node Z-score is calculated as follows:
zk =
∆Lk − ∆L
σ
(1)
where ∆Lk is the change of the ASPL under removal of node k, ∆L is the change of the ASPL under
node removal averaged over all protein residues and σ is the corresponding standard deviation.
We considered those nodes that exhibited a value ≥ 2 as central (for more details, see [25,49]).
For comparison to the binding modes identified in [3], we focused on central residues at the interface
between the two chains. Figure A1 illustrates an example of a RIN generated from the best docking
pose of ETS(Ets-1)/BRCT(TP53BP1).
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generated from the best docking pose of the ETS domain of Ets-1 (PDB ID: 1GVJ) and the second 
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